The effect of vitamin D levels on prognosis of patients with facial paralysis

Yıl 2020, Cilt: 30 Sayı: 4, 118 - 122, 15.12.2020

Ayşe Enise Göker Semih Karaketir Maide Hacer Alagöz Ayca Başkadem Yılmazer Hüseyin Sarı Hasan Sami Bircan Nilgün Başaran

Öz

Objectives: This study aims to investigate the serum 25-hydroxyvitamin D3 [25 OH D3] levels of patients with Bell’s palsy BP , and to evaluate their role in prognosis and their impact on the disease etiology. Patients and Methods: A total of 49 patients 30 males, 19 females; mean age: 42.2±13.6 years; range, 19 to 67 years who were diagnosed with BP and treated at our clinic between October 2019 and April 2020 were included. Blood samples were collected within 24 h after the onset of BP symptoms, and a standard oral pharmacological treatment was administered with prednisolone 1 mg/kg for 10 days and acyclovir 700 mg/day for six days. All patients were graded according to the House-Brackmann scale HBS . The patients were divided into three groups as Grade 2, Grade 3, Grade ≥4. The patients with BP were further divided into two groups as healed n=36 and not-healed ones n=13 . The vitamin D levels of the groups were compared. Results: Eleven 22% patients were in the Grade 2 group, 21 43% patients were in the Grade 3 group, and 17 35% patients were in the Grade ≥4 group. A significant decrease in vitamin D levels was observed in the patients with HBS Grade ≥4, compared to Grade 3 and Grade 2 groups p=0.002 and p<0.001, respectively . Vitamin D levels were significantly higher among the patients without sequelae than those with sequelae p<0.001 . Conclusion: Our study results indicate that vitamin D deficiency can affect prognosis of BP patients.

Anahtar Kelimeler

Bell’s palsy, facial paralysis, vitamin D deficiency

Kaynakça

• Adour KK. Current concepts in neurology: Diagnosis and management of facial paralysis. N Engl J Med 1982;307:348-51.
• Fisch U. Management of intratemporal facial nerve injuries. J Laryngol Otol 1980;94:129-34.
• Murthy JM, Saxena AB. Bell's palsy: Treatment guidelines. Ann Indian Acad Neurol 2011;14(Suppl 1):S70-2.
• Baugh RF, Basura GJ, Ishii LE, Schwartz SR, Drumheller CM, Burkholder R, et al. Clinical practice guideline: Bell’s palsy. Otolaryngol Head Neck Surg 2013;149(3 Suppl):S1-27.
• Wrzosek M, Łukaszkiewicz J, Wrzosek M, Jakubczyk A, Matsumoto H, Piątkiewicz P, et al. Vitamin D and the central nervous system. Pharmacol Rep 2013;65:271-8.
• Holick MF. Vitamin D for health and in chronic kidney disease. Semin Dial 2005;18:266-75.
• Holick MF. Vitamin D deficiency. N Engl J Med 2007;357:266-81.
• Eyles DW, Smith S, Kinobe R, Hewison M, McGrath JJ. Distribution of the vitamin D receptor and 1 alpha-hydroxylase in human brain. J Chem Neuroanat 2005;29:21-30.
• Jones G, Strugnell SA, DeLuca HF. Current understanding of the molecular actions of vitamin D. Physiol Rev 1998;78:1193-231.
• Vanherwegen AS, Gysemans C, Mathieu C. Regulation of immune function by vitamin D and its use in diseases of immunity. Endocrinol Metab Clin North Am 2017;46:1061-94.
• Laird E, McNulty H, Ward M, Hoey L, McSorley E, Wallace JM, et al. Vitamin D deficiency is associated with inflammation in older Irish adults. J Clin Endocrinol Metab 2014;99:1807-15.
• Guyton KZ, Kensler TW, Posner GH. Cancer chemoprevention using natural vitamin D and synthetic analogs. Annu Rev Pharmacol Toxicol 2001;41:421-42.
• Cornet A, Baudet C, Neveu I, Baron-Van Evercooren A, Brachet P, Naveilhan P. 1,25-Dihydroxyvitamin D3 regulates the expression of VDR and NGF gene in Schwann cells in vitro. J Neurosci Res 1998;53:742-6.
• Baas D, Prüfer K, Ittel ME, Kuchler-Bopp S, Labourdette G, Sarliève LL, et al. Rat oligodendrocytes express the vitamin D(3) receptor and respond to 1,25-dihydroxyvitamin D(3). Glia 2000;31:59-68.
• Holick MF. Vitamin D status: Measurement, interpretation, and clinical application. Ann Epidemiol 2009;19:73-8.
• Alberton DL, Zed PJ. Bell’s palsy: A review of treatment using antiviral agents. Ann Pharmacother 2006;40:1838-42.
• Tiemstra JD, Khatkhate N. Bell's palsy: Diagnosis and management. Am Fam Physician 2007;76:997-1002.
• Chun RF, Liu PT, Modlin RL, Adams JS, Hewison M. Impact of vitamin D on immune function: Lessons learned from genome-wide analysis. Front Physiol 2014;5:151.
• Veldman CM, Cantorna MT, DeLuca HF. Expression of 1,25-dihydroxyvitamin D(3) receptor in the immune system. Arch Biochem Biophys 2000;374:334-8.
• Sadeghi K, Wessner B, Laggner U, Ploder M, Tamandl D, Friedl J, et al. Vitamin D3 down-regulates monocyte TLR expression and triggers hyporesponsiveness to pathogen-associated molecular patterns. Eur J Immunol 2006;36:361-70.
• Kim TH, Lee B, Kwon E, Choi SJ, Lee YH, Song GG, et al. Regulation of TREM-1 expression by 1,25-dihydroxyvitamin D3 in human monocytes/ macrophages. Immunol Lett 2013;154:80-5.
• Abou-Raya S, Helmii M, Abou-Raya A. Bone and mineral metabolism in older adults with Parkinson's disease. Age Ageing 2009;38:675-80.
• Chabas JF, Stephan D, Marqueste T, Garcia S, Lavaut MN, Nguyen C, et al. Cholecalciferol (vitamin D₃) improves myelination and recovery after nerve injury. PLoS One 2013;8:e65034.
• Peitersen E. Bell’s palsy: the spontaneous course of 2,500 peripheral facial nerve palsies of different etiologies. Acta Otolaryngol Suppl 2002;(549):4-30.
• Heckmann JG, Urban PP, Pitz S, Guntinas-Lichius O, Gágyor I. The diagnosis and treatment of idiopathic facial paresis (Bell’s palsy). Dtsch Arztebl Int 2019;116:692-702.
• Barlow PG, Svoboda P, Mackellar A, Nash AA, York IA, Pohl J, et al. Antiviral activity and increased host defense against influenza infection elicited by the human cathelicidin LL-37. PLoS One 2011;6:e25333.
• Zhao Y, Ran Z, Jiang Q, Hu N, Yu B, Zhu L, et al. Vitamin D alleviates rotavirus infection through a Microrna-155-5p mediated regulation of the TBK1/ IRF3 signaling pathway in vivo and in vitro. Int J Mol Sci 2019;20:3562.
• Şenkal E, Ünüvar E, Seren L, Göl C, Durankuş F. D vitamini bakılmasının gerekliliği ve düzeylerinin yorumu. Çocuk Dergisi 2018;18:97-102.